← Oncology Approval Tracker

FDA DECISION ·

Zejula tablets

niraparib · GlaxoSmithKline

FDA approvalNew formulationOvarian and related cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

New tablet presentation for maintenance after a response to first-line platinum in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, or after platinum response in recurrent disease with a qualifying germline BRCA alteration.

LAMPGEN ANALYSIS

Why it matters

The tablet approval covered first-line maintenance and a biomarker-restricted recurrent maintenance use.

What research teams should watch

Verify treatment setting, response to platinum and germline BRCA status where required, and reconcile capsule and tablet strengths.

PRIMARY RECORDS

Sources